These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10572612)

  • 1. Phase I study of Doxil and vinorelbine in metastatic breast cancer.
    Burstein HJ; Ramirez MJ; Petros WP; Clarke KD; Warmuth MA; Marcom PK; Matulonis UA; Parker LM; Harris LN; Winer EP
    Ann Oncol; 1999 Sep; 10(9):1113-6. PubMed ID: 10572612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of Doxil and vinorelbine in patients with advanced malignancies.
    Laufman LR; Spiridonidis CH; Jones JJ; Rhodes V; Rossi K; Wallace K
    Cancer Invest; 2004; 22(3):344-52. PubMed ID: 15493354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
    Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
    Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
    Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
    Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
    Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.
    Nolè F; de Braud F; Aapro M; Minchella I; De Pas TM; Zampino MG; Monti S; Andreoni G; Goldhirsch A
    Ann Oncol; 1997 Sep; 8(9):865-70. PubMed ID: 9358936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of intravenous navelbine and doxorubicin combination in previously untreated advanced breast carcinoma.
    Pawlicki M; Rolski J; Zaluski J; Siedlecki P; Ramlau C; Tomzak P
    Oncologist; 2002; 7(3):205-9. PubMed ID: 12065792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
    Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
    Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
    Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
    Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
    Hess D; Thürlimann B; Pagani O; Aebi S; Rauch D; Ballabeni P; Rufener B; Castiglione-Gertsch M; Goldhirsch A;
    Ann Oncol; 2004 Dec; 15(12):1760-5. PubMed ID: 15550580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
    Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
    Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
    Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
    Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
    Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
    Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
    Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
    Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer.
    Hegg R; Costa MA; Perdicaris M; Delgado GL; Cabral-Filho S; Malzyner A; Caponero R; Yamagushi N; Novaes N; Anelli A; Correa M; Nader L; Andrade C
    Curr Med Res Opin; 2001; 16(4):225-34. PubMed ID: 11268706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.